A phase I, randomized, placebo‐controlled study of molnupiravir in healthy Japanese to support special approval in Japan to treat COVID‐19

Molnupiravir (MK‐4482) is an oral prodrug of the antiviral ribonucleoside analog, N‐hydroxycytidine (NHC), which has activity against RNA viruses, including severe acute respiratory syndrome‐coronavirus 2 (SARS‐CoV‐2). We conducted a phase I safety and pharmacokinetic study of molnupiravir in health...

Descripción completa

Detalles Bibliográficos
Autores principales: Nakamura, Keisuke, Fujimoto, Katsukuni, Hasegawa, Chihiro, Aoki, Ikuo, Yoshitsugu, Hiroyuki, Ugai, Hiroyuki, Yatsuzuka, Naoyoshi, Tanaka, Yoshiyuki, Furihata, Kenichi, Maas, Brian M., Wickremasingha, Prachi K., Duncan, Kelly E., Iwamoto, Marian, Stoch, Selwyn A., Uemura, Naoto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9538808/
https://www.ncbi.nlm.nih.gov/pubmed/36053806
http://dx.doi.org/10.1111/cts.13395

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9538808/
https://www.ncbi.nlm.nih.gov/pubmed/36053806
http://dx.doi.org/10.1111/cts.13395

Ejemplares similares